Daré Bioscience, Inc.

Daring to be different

General Information
Company Name
Daré Bioscience, Inc.
Founded Year
2015
Location (Offices)
San Diego, United States +1
Founders / Decision Makers
Number of Employees
25
Industries
Biopharma, Biotechnology, Health Care
Funding Stage
Post Ipo Debt
Social Media

Daré Bioscience, Inc. - Company Profile

Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene®, which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month, without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology. Daré’s EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Daré is developing a topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra®, for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer.

Funding Rounds & Investors of Daré Bioscience, Inc. (9)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Debt $22.00M 1 XOMA 29 Apr 2024
Grant Unknown 1 The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 13 Dec 2023
Grant $385.00K 1 The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 31 Jul 2023
Grant $584.99K 1 15 Nov 2022
Grant $900.00K 1 21 Sep 2020

View All 9 Funding Rounds

Latest News of Daré Bioscience, Inc.

View All

No recent news or press coverage available for Daré Bioscience, Inc..

Similar Companies to Daré Bioscience, Inc.

View All
Spiritus Bioscience - Similar company to Daré Bioscience, Inc.
Spiritus Bioscience Improve existing strategies of drug delivery for some of the most pressing mental health issues of our time.
Enteris BioPharma, Inc. - Similar company to Daré Bioscience, Inc.
Enteris BioPharma, Inc. The Preferred Partner in the Oral Drug Delivery of BCS III and BCS IV Compounds
Concept Matrix Solutions, Inc. - Similar company to Daré Bioscience, Inc.
Concept Matrix Solutions, Inc. R&D of therapeutic consumer and medical products. 🌱 Helping new and existing brands from concept to completion.